Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

ASMQ (Malaria)


ASMQ to treat Malaria

Fixed dose combination of Artesunate + Mefloquine

First new malaria treatment made in Latin America,
for Latin America and South East Asia!

  • Launched in 2008
  • Developed by an innovative collaboration between DNDi, Brazil and South-East Asia within the FACT Project Consortium
  • Produced by Farmanguinhos/Fiocruz (Brazilian public pharmaceutical company)
  • The 2-in-1 combination ensures that both drugs are taken together in correct proportions
  • Simple and Adapted Regimen for Children and Adults. As Easy as 1-2-3!
  • Adapted Packaging: 3 years shelf life: the longest shelf life of any FDC for malaria.
  • High compliance and low risk of resistance
  • WHO Prequalification in September 2012
  • Registered in Brazil in 2008, in India in 2011, in Malaysia and Myanmar in 2012, in Vietnam in 2014
  • Successful South-South technology transfer from Farmanguinhos to Cipla Ltd, India
  • Admission of Farmanguinhos/Fiocruz to the PAHO Strategic Fund in April 2013 will allow procurement by South American national control programs
  • Soon available in other countries in Latin America and Southeast Asia

Download ASMQ brochure, September 2012 [1.9MB]
Download ASMQ scientific document, September 2012 [1.3MB]
Download ASMQ press pack, April 2008 [1.1MB]
Read more about ASMQ project

   ASMQ News

Implementation progress

ASMQ: registered in Vietnam!

ASMQ: WHO Prequalified in September 2012!

Farmanguinhos/Fiocruz admitted to PAHO Strategic Fund

1'200'000 treatments distributed

Recent Scientific Publications
Malaria Journal, February 2013
The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License